Fig. 4From: An international survey of healthcare providers’ knowledge of cardiac complications of cancer treatmentsResponses to clinical scenario #1: A 50 year old female has received 12 cycles of trastuzumab/pertuzumab therapy for Her-2/neu positive metastatic breast cancer. Her ejection fraction at baseline was 55%, but on repeat echocardiogram decreased to 30%. She has no cardiac symptoms. What would be your management of the patient at this time?Back to article page